At Oncolinx, Inc, our vision is to translate science and innovation into better patient outcome. Through the Breast Cancer Startup Challenge, we have been given the unique opportunity to take a technology through the clinical development process to make a meaningful impact on health. Our invention specifically is a novel class of cancer toxins that have the potential to improve the safety and efficacy of current antibody therapies and other targeted therapeutics. The novel cancer toxin could empower targeted therapeutic options for a variety of patient populations and multiple cancer indications.
Thus far our team has developed a draft of the clinical development plan for the invention with mentors and experts in the oncology world, as well as connected with industry partners who are interested in using our technology on some of their current targets to improve the efficacy of their technologies, and in turn, help us generate data. As a team we are excited to persevere down this path and collaborate with the Center for Advancing Innovation, Avon Foundation, Rutgers University, and the National Cancer Institute to make a positive impact in oncology.
Thus far our team has developed a draft of the clinical development plan for the invention with mentors and experts in the oncology world, as well as connected with industry partners who are interested in using our technology on some of their current targets to improve the efficacy of their technologies, and in turn, help us generate data. As a team we are excited to persevere down this path and collaborate with the Center for Advancing Innovation, Avon Foundation, Rutgers University, and the National Cancer Institute to make a positive impact in oncology.
RSS Feed